Sanofi enrolls adults in trials of an experimental mRNA vaccine against acne
The French company Sanofi has begun enrolling participants aged 18–45 in two clinical trials of an experimental mRNA vaccine for acne: one will cover 800 people with moderate-to-severe forms, the other 228 people with mild acne. The trials combine phases 1 and 2 and will assess safety, immune response, and effect.
Madina Usmonova